ArticleHealthcare policy = Politiques de sante2013
Cost-control mechanisms in Canadian private drug plans.
Article in Healthcare policy = Politiques de sante, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Universal Free Contraception Coverage Policy, Out-of-Pocket Payments, and Costs.JAMA health forum · 2026Article
- Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Costs of major depression covered / not covered in British Columbia, Canada.BMC health services research · 2023Article
- Inequity in insurance coverage for prescription drugs in New Brunswick, Canada.Canadian journal of public health = Revue canadienne de sante publique · 2022Article
- Trends in Canadian prescription drug purchasing: 2001-2020.Journal of pharmaceutical policy and practice · 2022Article
- It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada".International journal of health policy and management · 2020Article
- Pharmacare in Canada: The paediatric perspective.Paediatrics & child health · 2020Review
- Impact of brand drug discount cards on private insurer, government and patient expenditures.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Should national pharmacare apply a value-based insurance design?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Evaluation of Prescription Adaptation Following Changes to A Provincial Drug Insurance Formulary.Pharmacy (Basel, Switzerland) · 2019Article
- Canada's universal health-care system: achieving its potential.Lancet (London, England) · 2018Review
- The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.CMAJ open · 2018Article
- Universal prescription drug coverage in Canada: Long-promised yet undelivered.Healthcare management forum · 2016Review
- The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada.Healthcare policy = Politiques de sante · 2015Article
- The increasing inefficiency of private health insurance in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 68% of Canadians receive prescription drug coverage through an employer-sponsored private plan. However, we have very limited data on the structure of these plans. This study aims to identify and describe the use of cost-control mechanisms in private drug plans in Canada and describe what private coverage looks like for the average Canadian. Using 2010 data from over 113,000 different private drug plans, provided by Applied Management Consultants, we determined the overall use of key cost-control measures, and the cost-control tools that appear to be gaining currency compared to a report on benefits coverage in 1998. We found that the use of common cost-control measures is relatively low among Canadian private benefits programs. Co-insurance is much more common in private coverage plans than co-payments. Deductibles are uncommon in Canada and, when in place, are very small. The use of annual and lifetime maximums is increasing. Canadian private benefits programs use few cost-control measures to respond to increasing costs, particularly in comparison to their public counterparts. These results suggest there are ample opportunities for greater efficiency in private sector drug coverage plans.
Indexed as
Identifiers
23968672PMC3999546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.